Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Number fever: The Pepsi contest that became a deadly fiasco
10:23am, Tuesday, 04'th Aug 2020
DECADES ago, a marketing stunt promised Philippine soda drinkers a chance at a million pesos. But an error at a bottling plant led to 600,000 winners—and to lawsuits, rioting, and even deaths.
Nisa Investment Advisors LLC Sells 14,860 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
06:52am, Tuesday, 04'th Aug 2020
Nisa Investment Advisors LLC decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 65.5% during the second quarter, according to the company in its most recent disclosure with the Se
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
09:15pm, Monday, 03'rd Aug 2020
Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
08:37pm, Monday, 03'rd Aug 2020
Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours.
Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
08:01pm, Monday, 03'rd Aug 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance.
Zurcher Kantonalbank Zurich Cantonalbank Has $2.71 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
10:04am, Monday, 03'rd Aug 2020
Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 17.1% during the second quarter, according to its most recent disclosure with the
Winning the cold war with China will require a stronger military and a more inventive economy
10:00am, Monday, 03'rd Aug 2020
The United States must counter the rise of China with a stronger military and a renewal of the U.S. economy.
Vident Investment Advisory LLC Increases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
09:32am, Monday, 03'rd Aug 2020
Vident Investment Advisory LLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 58.9% during the 2nd quarter, according to the company in its most recent 13F filing with th
Janney Montgomery Scott LLC Buys 172 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
08:10am, Monday, 03'rd Aug 2020
Janney Montgomery Scott LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commi
The Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market will grow by USD 909.86 mn during 2020-2024
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020
08:01pm, Thursday, 30'th Jul 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and
Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
04:44pm, Tuesday, 28'th Jul 2020
The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
04:31pm, Monday, 27'th Jul 2020
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
